Use of the specific binding ratio distribution to characterise multiple system atrophy in advanced iodine-123-labelled N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane serotonin transporter imaging

Document Type : Original Article

Authors

1 Department of Radiology, Fujita Health University School of Medicine, Aichi, Japan

2 Section of Radiology, Fujita Health University Hospital, Aichi, Japan

3 Department of Neurology, Fujita Health University

4 Department of Neurology, Fujita Health University School of Medicine, Aichi, Japan

5 Canon Medical Systems, Otawara, Tochigi, Japan

Abstract

Objective(s): Sudden death in multiple system atrophy (MSA) is caused by decreased serotonergic innervation, but there is no routine test method for this decrease. In addition to dopamine transporters, iodine-123-labelled N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (123I-FP-CIT) binds serotonin transporters (SERTs). We noted a binding potential to quantify the total quantity of 123I-FP-CIT binding to its receptors.
Following Mintun’s binding-potential concept, this study aimed to evaluate the relationship between the specific binding ratio (SBR) and total SERT tissue amount, but not SERT binding, and to develop an SBR imaging method to measure brain-stem SERT. We sought to establish a binding-potential imaging procedure using SBR images to examine differences in the brain-stem SERT distribution between healthy subjects and MSA patients.
Methods: Single-photon emission computed tomography (SPECT) and T1-weighted magnetic resonance (MR) images were aligned. The MR (T1) images were used to set a reference site for the occipital-lobe SBR in each subject, and measurements were made from the SPECT image at the same position. The pixel values and accumulation ratios compared with the occipital lobe were calculated, and a regional SBR distribution image was created. We identified areas with SERT accumulation above a certain level.
Results: The SERT accumulation site was visualised as an SBR value on MR images. The accumulation distribution (SERT distribution) on the SBR images significantly differed between the healthy subjects and patients with MSA.
Conclusion: SERT accumulation was noted in the brain-stem region, indicating that SBR imaging was useful for viewing and quantifying SERT accumulation.

Keywords

Main Subjects

References

  1. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography.Ann Neurol. 1984; 15(3); 217-227.
  2. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, cross-over study in healthy control subjects. J Nucl Med. 2007; 48(3); e359-e366.
  3. Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012; 53(7); 1087-1090.
  4. De Win MM, Habraken JB, Reneman L, Van den Brink W, den Heeten GJ, Booij J. Validation of [123I]β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuro psycho-pharmacology. 2005; 30; e996-e1005.
  5. Kerenyi L , Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003; 60(9); e1223-e1229.
  6. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's Eur J Neurol. 2007; 14(5); e523-e528.
  7. Chou KL, Dayalu P, Koeppe RA, Gilman S, Spears CC, Albin RL, et al. Serotonin transporter imaging in multiple system atrophy and Parkinson's disease. Mov Disord. 2022; 37(11); e2301-e2307.
  8. Nicastro N, Fleury V, Broc N, Burkhard PR, Garibotto V. Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinso-nisms. Parkinsonism Relat Disord. 2020; 78; 38-43.
  9. Joling M, Vriend C, Van den Heuvel OA, Raijmakers PG, Jones PA, Berendse HW, et al. Analysis of extrastriatal 123I-FP-CIT binding contributes to the differential diagnosis of parkinsonian diseases. J Nucl Med. 2017; 58(7); e1117–e1123.
  10. Nicastro N, Garibotto V, Burkhard PR. Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort. BMC Neurol. 2020; 20; 192.
  11. Licho R, Glick SJ, Xia W, Pan TS, Penney BC, King MA. Attenuation compensation in 99mTc-SPECT brain imaging: A comparison of the use of attenuation maps derived from transmission versus emission data in normal scans. J Nucl Med. 1999; 40; e456-e463.
  12. Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T, et al. Effects of scatter and attenuation correction on quantitative analysis of beta-CIT brain SPET. Nucl Med Commun. 1999; 20(2); e159-e165.
  13. Inui Y, Ichihara T, Uno M, Ishiguro M, Ito K, Kato K, et al. CT-based-attenuation correction and resolution compensation for I-123 IMP brain SPECT normal database: a multicenter phantom study. Ann Nucl Med. 2018; 32(5); e311-e318.
  14. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Involvement of medullary serotonergic groups in multiple system atrophy. Ann Neurol. 2004; 55(3); 418-422.
  15. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Depletion of putative chemo-sensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. Brain. 2007; 130(Pt 2); 469-475.
  16. Tada M, Kakita A, Toyoshima Y, Onodera O, Ozawa T, Morita T, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain. 2009; 132(Pt 7); e1810-e1819.
  17. Riku Y, Watanabe H, Mimuro M, Iwasaki Y, Ito M, Katsuno M, et al. Non–motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei. J Neurol. 2017; 264; e2249-e2257.
  18. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9); e670-e676.
  19. Van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med. 1995; 36(7); e1175-e1181.
  20. Kouris K, Clarke GA, Jarritt PH, Townsend CE, Thomas SN. Physical performance evaluation of the Toshiba GCA-9300A triple-headed system. J Nucl Med. 1993; 34; 1778-1789.
  21. Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med. 1993; 34(12); 2216-2221.
  22. Matsuda H. Brain SPECT Perfect Guide, Chapter 3 SPECT apparatus (3) GCA9300R. Medica; 2018. 317-323.
  23. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006; 33; 1491-1499.
  24. Abdo WF, De Jong D, Hendriks JCM, Horstink MWIM, Kremer BPH, Bloem BR, et Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord. 2004; 19(5); e571-e579.
  25. Azmitia EC, Singh JS, Whitaker-Azmitia PM. Increase serotonin axons (immunoreactive to 5-HT transporter) in postmortem brains from young autism fonors. Neuro pharmacology 2011; 60(7-8):1347-1354.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 13, Issue 1
January 2025
Pages 33-41

Files

Share

How to cite

Statistics